Open Access

Table II

Critical analysis of the literature on the efficacy of botulinum toxin in the management of mouth opening limitation.

Reference Objective Type of study No. BT dose Duration Judgment criteria Muscle site Validity
Fietzek, 2009 [14] Efficiency: MO increase Rand, DB, CT 2 centers 11 5000 U Neurobloc** 6 weeks Objective: IDS, saliva rate, MO M S
Guarda-Nardini, 2012 [15] Efficacy: decrease in pain and increase MO Rand, CT; SB 30 150 U Dysport* 3 months Subjective: VAS M + T S
Objective: MO S
Kurtoglu, 2010 [16] Efficiency: decreased pain and increased MO Rand, DB, CT 24 30 U Botox* 1 month Subjective: VAS M + T S
Objective: MO with EMG S
Denglehem, 2010 [17] Efficacy: decreased pain Rand, DB, CT 30 50 U Botox* 1 month Subjective: VAS with pressure M + T S
Objective: Muscular activity with EMG S
Sidebottom, 2012 [18] Efficiency: decreased pain and increased MO Prospective, statistical analysis 62 50 U Dysport* 3 weeks Subjective: VAS M + T + P S
Objective: MO   S

Rand: randomized; DB: double-blind; SB: single-blind; CT: clinical trial; U: Unit; No.: number; BT: Botulinum toxin; VAS: visual analog scale; MO: mouth opening; IDS: interdental space; EMG: electromyogram; M: masseter; T: temporal; P: medial pterygoid; US: unspecified; S: significant.

*

By injection.

**

In total.

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.